Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2000
11/22/2000CN1273823A Analgesic composition for cancers in digestive system
11/22/2000CN1273822A Oral liquid of L-arginine for treating cardiovascular and cerebrovascular diseases and its preparing process
11/22/2000CN1273821A Application of sesquiterpenoid as acetylcholineserase reactivator
11/22/2000CN1273820A Process for preparing Chinese-medicinal pills containing borneol
11/22/2000CN1058724C Use of steroid compound for preparing medicaments
11/22/2000CN1058723C D4T polymorphic form I process
11/22/2000CN1058718C Optically active benzothiepin derivative, its prepn. and use
11/22/2000CN1058715C Thiophene compound, its prepn. method and medicinal compsn. containing same
11/22/2000CN1058712C Microbicidal triazolyl derivatives
11/22/2000CN1058710C Benzamide derivatives, process for prepn. thereof and pharmaceutical compsn. comprising same
11/22/2000CN1058709C Amide compounds for medical treatment
11/22/2000CN1058708C Quinolone derivative for treatment of urinary incontinence, its prepn. method and application
11/22/2000CN1058705C Substituted benzene sulfone urea, benzensulfonyl thiourea its prepn., its application as medicine or diagnostic medicine and drugs containing it
11/22/2000CN1058639C Biological compatibility aquogel based on cross-linked plyacrylamide in application of preparing inner repairing objects of human body for injection
11/22/2000CN1058614C Galenic prepn. compsn.
11/22/2000CN1058609C Medical application of compound morusin
11/21/2000US6150557 Compounds
11/21/2000US6150539 Triptolide prodrugs having high aqueous solubility
11/21/2000US6150532 Modulators of proteins with phosphotyrosine recognition units
11/21/2000US6150530 Amidation of amine with acid
11/21/2000US6150526 Piperidine derivative having renin inhibiting activity
11/21/2000US6150524 Morphine derivatives with analgesic activity
11/21/2000US6150424 Comprising a melt-processable thermoplastic polymer and a volatile, physiologically acceptable blowing agent
11/21/2000US6150423 Propofol-based anesthetic and method of making same
11/21/2000US6150421 Treatment of estrogen-receptor positive breast cancer and estrogen-receptor negative breast cancer with retinoid with CH2 OH at the side chain terminal position
11/21/2000US6150420 By administering buproprion or salt and carrier intranasally; treating nicotine addiction, depression
11/21/2000US6150419 Agmatine as a treatment for neuropathic pain
11/21/2000US6150418 Propellant-free concentrate suitable for storage containing given concentration of formoterol, or salt or addition products thereof as active substance in a solvent or suspension agent; use in inhalation therapy
11/21/2000US6150417 Administering to warm blooded animals compounds such as n-tert-butyl-5-((2-(2-methoxyphenoxy)ethyl)amino)pentanamide for inducing antiemetic activity; treating anxiety, depression, and sleep disorders
11/21/2000US6150416 2-hydroxy-3-(substitued benzyl)-n,n'-bis(substituted carbonyl)-n-(substituted)-1,3-propanediamine based compounds; use in the detection, labelling and inhibition of cathepsin d
11/21/2000US6150415 Epoxide hydrolase complexes and methods therewith
11/21/2000US6150414 Inhibiting a virus causing infection (such as hiv) by administering the compound 1,3,4,6-tetrahydroxy-7,16-dioxo-7,16-dihydro-dibenzo(a,o)perylene
11/21/2000US6150413 Treatment of dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as mammalian skin and hair conditions; 4-(4-(biphenyl-2-yl)but-3-en-1-ynyl)benzoic acid, for example
11/21/2000US6150412 Such as 4-(5-hydroxy-4-methoxy-2-nitrophenyl)butanoic acid; administering to inhibit catechol-o-methyl transferase; treating parkinson's disease or hypertension
11/21/2000US6150411 Treating dyslexia by administering to a subject docosahexaenoic acid (dha)
11/21/2000US6150410 Acidic drug such as divalproex sodium dissolved or dispersed in a polymeric matrix of a neutral, water-swellable, hydrophilic polymer, and acid soluble polymer water swellable above ph 5; uniform release in stomach and intestines
11/21/2000US6150409 Adjuvants and methods for raising intracellular calcium ion concentration
11/21/2000US6150407 In a tissue or organ by contacting with a compound of given formula such as methyl-3,5-diiodo-4-(4'-methoxyphenoxy)benzoate; reducing the level of tumor necrosis factor alpha
11/21/2000US6150405 Hair loss treatment with ascorbates
11/21/2000US6150403 Topical compositions for regulating the oily/shiny appearance of skin
11/21/2000US6150402 Natriuretic compounds
11/21/2000US6150401 Use of MEK1 inhibitors as protective agents against damage due to ischemia
11/21/2000US6150400 Method for treating vulvar vestibulitis
11/21/2000US6150398 By administering to a human a synergistic combination of paclitaxel and a dna crosslinking antineoplastic agent, such as cisplatin
11/21/2000US6150397 5-aroylnaphthalene derivatives as anti-inflammatory agents
11/21/2000US6150396 Methods of treating or preventing interstitial cystitis
11/21/2000US6150395 Indole-3-carbinol (I3C) derivatives and methods
11/21/2000US6150392 Administering histidine to inhibit cytokines and growth factors without interfering with host defense mechanisms; damage from restenosis, burns, surgical procedures; antiproliferative and -carcinogenic agents; antiallergens
11/21/2000US6150390 Accelerates bone formation; osteoporosis; (ltb-4(leukotriene-b-4; 5,12-dihydroxyeicosatetra-6,8,10,14-enoic acid) receptor antagonist
11/21/2000US6150388 Indole derivatives as 5-HT1 agonists
11/21/2000US6150387 With the exception of alcohol abuse, preventing or reducing self-administration of a drug or a substance capable of giving rise to pharmacomania or to overuse e.g., nicotine, caffeine, benzodiazepines, narcotics and hallucinogens
11/21/2000US6150385 Viricide with activity against cytomegalo virus (cmv), herpes virus including varicella zoster virus, the epstein-barr virus, the herpes simplex virus, and the human herpes virus type 8 (hhv-8)
11/21/2000US6150384 Pharmaceutical composition
11/21/2000US6150383 Comprising an insulin sensitivity enhancer in combination with one or more other antidiabetics differing from the enhancer in mechanism of action; lipid/glycometabolism disorders; antidiabetic agents; side effect reduction
11/21/2000US6150382 Enzyme inhibitors of blood coagulation factor xa, a serine protease class of enzymes; e.g., 4-hydroxy-3-((4-(2-carboxy-methyl)thio-6-(3-(1-methyl)-6-(3-(1 -methyl)imidazolin-2-yl)-phenoxy-3,5-difluoropyridine and derivatives
11/21/2000US6150381 Methods of treating microbial infection and therapeutic formulations therefor
11/21/2000US6150380 Crystalline form of omeprazole
11/21/2000US6150378 Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
11/21/2000US6150377 Farnesyl protein transferase inhibitors; anticarcinogenic,-tumor and -proliferative agents; also psoriasis, benign prostatic hypertrophy or restinosis; infections facilitated by farnesyl protein transferase, e.g., malaria or hepatitus delta
11/21/2000US6150376 Bi- and tri-cyclic aza compounds and their uses
11/21/2000US6150375 Inhibitors of both of the human 5ar isozymes; benign prostate hyperplasia, male pattern baldness, acne vulgaris, seborrhea, androgenic alopecia, hirsutism and prostate cancer; blocks the conversion of testosterone to 5-alpha-dihydrotestosterone
11/21/2000US6150373 Bicyclic nitrogen heterocycles
11/21/2000US6150370 1,3-dinitrocyclic compound treats numerous diseases caused by undesired metalloprotease activity, such as tumor metastasis, osteoarthritis, rheumatoid arthritis, skin inflammation, ulcerations, and periodontitis
11/21/2000US6150366 Crystalline ziprasidone free base or crystalline ziprasidone hydrochloride particles with specific particle size are useful as antipsychosis agent
11/21/2000US6150365 Anxiety method
11/21/2000US6150364 Dissolving needle-shaped riboflavin of a stable modification form in an aqueous mineral acid solution with intermixing, adding active charcoal adosrbent to the solution to adsorb dissolve impurities, filtering, crystallizing the filtrate
11/21/2000US6150361 Therapeutically treating a diseased animal suffering from a parasitic neurologic or abortigenic disease comprising administering the animal ponazuril, a triazineone compound
11/21/2000US6150360 Administering to a patient suffering from human immunodeficiency virus infection a trisubstituted 1,3,5-triazine derivative
11/21/2000US6150359 Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
11/21/2000US6150358 Useful in the treatment of disease for which the use of anti-oxidation agent is requiered such as neurodegenrative disorders
11/21/2000US6150357 Adminstration of a therapeutically effective amount of an agonist of slowly activating cardiac delayed rectifier potassium current is selected from 1,4-benzodiazepin-2-one or spiro(benzopyran-peperidine)
11/21/2000US6150356 Potassium channel inhibitors and method
11/21/2000US6150354 Compounds for the treatment of Alzheimer's disease
11/21/2000US6150353 Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
11/21/2000US6150352 Antagonists of gonadotropin releasing hormone
11/21/2000US6150351 Cephem compounds and pharmaceutical use thereof
11/21/2000US6150350 Carbapenem antibiotic and beta-lactamase inhibitor, useful for the treatment and prophylaxis of infectious diseases
11/21/2000US6150349 Methods for treating psychosis associated with glucocorticoid related dysfunction
11/21/2000US6150348 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
11/21/2000US6150347 Use of aldosterone antagonists to inhibit myocardial fibrosis
11/21/2000US6150346 Method and composition for treating or preventing osteoporosis
11/21/2000US6150345 Methods for promoting survival of myelin producing cells
11/21/2000US6150343 10-hydroxy-7-substituted silylcamptothecin derivative is used as anticarcinogenic and antitumor agent
11/21/2000US6150342 Heparin derivatives for treatment of angina pectoris
11/21/2000US6150341 Reacting the 5'oh group of vb12 or an analogue thereof with a bifunctional carbonyl electrophile to form an active intermediate, and subsequently reacting the intermediate with a nucleophilic spacer molecule to yield vb12 derivative
11/21/2000US6150339 Anti-viral guanosine-rich oligonucleotides
11/21/2000US6150337 Ribavirin is used to suppress type 2-mediated t cell responses and promote type 1-mediated t cell response
11/21/2000US6150330 Parenteral administration to the animal of a substantially aqueous biologically active bovine growth hormone releasing factor analog comprising at least 50 mg of said biologically active bovine hormone releasing factor analog in water
11/21/2000US6150153 Thermostable trehalose-releasing enzyme
11/21/2000US6150131 Screening for viricides that suppress interactions between cysteine and palmitic acid; mix cells infected with influenza virus, palmitic acid and modulator, monitor reduction in palmitic acid incorporation
11/21/2000US6150129 Antimicrobial determination of N-(aminoalkyl) and/or N-(Amidoalkyl) dinitrogen heterocyclic compositions
11/21/2000US6150116 Transcription factor DP-1 antibody
11/21/2000US6150101 Methods of identifying a composition that alters connective tissue growth factor expression
11/21/2000US6150091 Direct molecular diagnosis of Friedreich ataxia
11/21/2000US6149944 Mixing aqueous phase containing water-soluble betalactam antibiotic agent and/or inhibitor of betalactamase and organic phase comprising biodegradable polymer is dissolved in solvent, dispersing, adding to aqueous phase; desolventizing
11/21/2000US6149943 Active drug is layered onto tcore via solution coating; coated particles have arrower particle size distribution
11/21/2000US6149940 Bioavailability; on contact with gastric juices, after rapid and considerable swelling of layers increases considerably in volume, thus, the pharmaceutical preparation remains in the stomach for longer; drug delivery, time release agents
11/21/2000US6149936 DNA expression vectors for the use in the gene therapeutic treatment of vascular disorders
11/21/2000US6149935 Solid matrix system for transdermal drug delivery
11/21/2000US6149931 Applying over and around retinal break a non-toxic polymer formulation comprising polymer precursor that is a poly(ethylene glycol) based polymer precursor, and transforming the polymer formulation into a gel-like coat
1 ... 6206 6207 6208 6209 6210 6211 6212 6213 6214 6215 6216 6217 6218 6219 6220 6221 6222 6223 6224 6225 6226 ... 7860